UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1

UT MD 安德森癌症中心网络领导学术参与网站 (LAP) UG1

• 批准号: 9886224
• 负责人: KELLY K HUNT
• 金额: $ 147.86万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-05 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9886224
• 关键词: Administrator; Adult; Advisory Committees; Area; Authorship; Blood; Blood specimen; Cancer Center; Caring; Clinical Investigator; Clinical Research; Clinical Trials; Clinical Trials Cooperative Group; Clinical Trials Network; Communication; Data; Development; Diagnostic Imaging; Discipline; Education; Enrollment; Ensure; Faculty; Funding; General Hospitals; Goals; Grant; Group Meetings; Gynecologic Oncology; Immunotherapy; Indigent; Institution; Intervention Studies; Intervention Trial; Lead; Leadership; Location; Malignant Neoplasms; Medical Oncology; Mentors; Mentorship; Minority; Mission; National Clinical Trials Network; Operative Surgical Procedures; Pathology; Patient Care; Patients; Peer Review Grants; Pharmacology; Phase; Phase II/III Clinical Trial; Play; Prevention education; Principal Investigator; Protocols documentation; Publications; Radiation Oncology; Rare Diseases; Reporting; Research; Research Design; Research Personnel; Resolution; Role; Services; Site; Surgical Oncology; Talents; Texas; Therapeutic; Time; Tissues; Translational Research; Underinsured; Uninsured; cancer therapy; data quality; early-career faculty; experience; faculty research; imaging approach; innovation; member; multidisciplinary; novel; operation; programs; protocol development; skills; success; tissue biomarkers; translational scientist; treatment trial

PROJECT SUMMARY Clinical trials are an integral part of MD Anderson Cancer Center’s (MDACC) mission. In FY2016, we cared for approximately 135,000 patients and enrolled more than 9,000 patients on nearly 1,000 interventional studies. MDACC has made significant contributions to the former NCI cooperative groups and the new National Clinical Trial Network (NCTN), including robust trial enrollment, scientific and administrative leadership, and mentoring early career faculty to participate in these important national trials. For FY 2014-2017, at MDACC, 858 patients were enrolled in NCTN Network group clinical trials, including 684 patients in therapeutic treatment trials resulting in an average of > 215 patients per year. Centralized coordination of NCTN activities at our institution has facilitated the development and conduct of multidisciplinary, innovative trials. This participation has led to opportunities for service through various NCTN leadership roles. Our institution has also sponsored talented clinical and translational investigators to apply for NCTN membership, provided mentorship of early career faculty, and encouraged applications for NCTN peer-reviewed grant funding. These activities have contributed to the success of the NCTN LAPS U10 grant as well as working towards the fulfillment of our mission of eliminating cancer in Texas, nationally, and globally through advances in cancer treatment, research and education. Our goals will continue with the newly proposed NCTN LAPS UG1 grant.

项目摘要 临床试验是MD安德森癌症中心（MDACC）使命的一个组成部分。2016财年，我们关注 约135，000名患者，并在近1，000项干预性研究中招募了9，000多名患者。 MDACC为前NCI合作组和新的国家临床研究中心做出了重大贡献。 试验网络（NCTN），包括强大的试验入组、科学和行政领导以及指导 早期的职业教师参加这些重要的国家试验。2014-2017财年，在MDACC，858名患者 参加了NCTN网络组临床试验，包括684例治疗试验患者， 平均每年超过215名患者。在我们机构集中协调NCTN活动， 促进了多学科创新试验的开发和实施。这种参与导致了 通过各种NCTN领导角色提供服务的机会。我们的机构还赞助了 临床和翻译研究者申请NCTN会员资格，提供早期职业生涯的指导 教师，并鼓励申请NCTN同行评审的赠款资金。这些活动有助于 NCTN LAPS U10赠款的成功，以及努力实现我们的使命， 通过在癌症治疗、研究和治疗方面的进步，在德克萨斯州、全国和全球消除癌症， 教育我们的目标将继续与新提出的NCTN LAPS UG 1赠款。